BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38515388)

  • 1. A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study.
    Chen M; Li L; Xia Q; Chen X; Liao Z; Wang C; Shen B; Zhou M; Zhang Q; Zhang Y; Qian L; Yuan X; Wang Z; Xue C; An X; Liu B; Gu K; Hou M; Wang X; Wang W; Li E; Zhong J; Cheng J; Shu Y; Yang N; Wang H; Yang R; Liu T; Deng T; Ma F; Liao W; Qiu W; Chen Y; Chen X; Zhang M; Xu R; Li X; Feng J; Ba Y; Shi Y
    Cancer; 2024 Apr; 130(S8):1524-1538. PubMed ID: 38515388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of rhTPO and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia in hematological tumors based on real-world data.
    Zhang JJ; Zhao R; Xia F; Li Y; Wang RW; Guan X; Zhu JG; Ma AX
    Ann Palliat Med; 2022 Aug; 11(8):2709-2719. PubMed ID: 36064361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)].
    Consensus Committee of Chemotherapy Induced Thrombocytopenia, Chinese Society of Clinical Oncology
    Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):714-720. PubMed ID: 30293399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Consensus on the clinical diagnosis, treatment and prevention of cancer treatment-induced thrombocytopenia in China (2023 edition)].
    ;
    Zhonghua Yi Xue Za Zhi; 2023 Sep; 103(33):2579-2590. PubMed ID: 37650204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and economic evaluation of rhTPO and rhIL-11 in the treatment of cancer therapy induced thrombocytopenia based on real-world research.
    Gong FM; Liu FY; Ma X; Ma ST; Xiao HT; Jiang G; Qi TT
    Front Pharmacol; 2024; 15():1288964. PubMed ID: 38327986
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efficacy of Recombinant Human Thrombopoietin and Recombinant Human Interleukin 11 for Treatment of Chemotherapy Indu-ced Thrombocytopenia in Acute Myeloid Leukaemia Patients].
    Tang G; Wang XM; Meng JX; Luan CL; Chen JF; Wu YQ; Zhang XN; He ZY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):234-238. PubMed ID: 29397850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of rhTPO and rhIL-11 on Thrombocytopenia after Chemotherapy in Leukemia].
    Dai JF; Xia RX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):711-717. PubMed ID: 35680794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential treatment with rmIL-3 or simultaneous treatment with rmIL-3 or rhIL-11 with thrombopoietin (TPO) fails to enhance in vivo neonatal rat thrombocytopoiesis.
    van de Ven C; Fernandez GW; Herbst T; Knoppel A; Cairo MS
    Exp Hematol; 1997 Aug; 25(9):1005-12. PubMed ID: 9257814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia].
    Bai CM; Zou XY; Zhao YQ; Han SM; Shan YD;
    Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):397-400. PubMed ID: 15061993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia.
    Soff GA; Ray-Coquard I; Rivera LJM; Fryzek J; Mullins M; Bylsma LC; Park JK
    PLoS One; 2022; 17(6):e0257673. PubMed ID: 35679540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
    Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy.
    Wu S; Zhang Y; Xu L; Dai Y; Teng Y; Ma S; Ho SH; Kim JM; Yu SS; Kim S; Song S
    Support Care Cancer; 2012 Aug; 20(8):1875-84. PubMed ID: 22041866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human thrombopoietin in critically ill patients with sepsis-associated thrombocytopenia: A clinical study.
    Liu Y; Jin G; Sun J; Wang X; Guo L
    Int J Infect Dis; 2020 Sep; 98():144-149. PubMed ID: 32561426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact on platelet recovery of recombinant human thrombopoietin in severe aplastic anemia patients with allogeneic hematopoietic stem cell transplantation].
    Song Y; Zhou F; Song NX; Liu XM; Yu Z; Xie LN; Song XC; Li X
    Zhonghua Xue Ye Xue Za Zhi; 2018 Mar; 39(3):207-211. PubMed ID: 29562465
    [No Abstract]   [Full Text] [Related]  

  • 15. Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study.
    Wu Q; Ren J; Wu X; Wang G; Gu G; Liu S; Wu Y; Hu D; Zhao Y; Li J
    J Crit Care; 2014 Jun; 29(3):362-6. PubMed ID: 24405656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
    Dai XF; Yu J; Liu L; Wu G
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):623-5. PubMed ID: 19102944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study.
    Liu X; Bai Y; Wang T; Song Y; Sun F; Xia R; Zhu F; Ma J; Lu Q; Ye X; Zhan X; Li L; Guo X; Cheng S; Li Y; Guo Z; Chen Y; Qian S; Qin L; Zhang Q; Cao S; Yang R
    Platelets; 2023 Dec; 34(1):2157806. PubMed ID: 36597010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical development of recombinant human interleukin 11 (NEUMEGA rhIL-11 growth factor).
    Kaye JA
    Stem Cells; 1996; 14 Suppl 1():256-60. PubMed ID: 11012229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia.
    Wang X; Bi H; Liu L; Liu Y; Yin L; Yao J; Yu J; Tao W; Wei Y; Li Y; Yin L; Mu H; Du Y; Zhou Z
    Platelets; 2023 Dec; 34(1):2271568. PubMed ID: 37941414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
    Vadhan-Raj S; Verschraegen CF; Bueso-Ramos C; Broxmeyer HE; Kudelkà AP; Freedman RS; Edwards CL; Gershenson D; Jones D; Ashby M; Kavanagh JJ
    Ann Intern Med; 2000 Mar; 132(5):364-8. PubMed ID: 10691586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.